Conv. Plasma
Nigella Sativa
Peg.. Lambda
Vitamin A
Vitamin C
Vitamin D

Feedback Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality, 24mg 30% Improvement Relative Risk Mortality, 12mg -3% Recovery time, 24mg 19% Recovery time, 12mg 6% Progression, 24mg 33% Progression, 12mg 18% Viral clearance, 24mg -33% Viral clearance, 12mg -18% George et al. CTRI/2020/05/025068 Ivermectin RCT LATE Favors ivermectin Favors control
George, 112 patient ivermectin late treatment RCT: 30% lower mortality [p=0.55], 19% faster recovery [p=0.37], 33% lower progression [p=0.41], and 33% worse viral clearance [p=0.5]
copied to clipboard
Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial
George et al., Indian Journal of Hematology and Blood Transfusion, doi:10.1007/s12288-022-01546-w
27 May 2022    Source   PDF   Share   Tweet
RCT with 35 single dose 24mg, 38 single dose 12mg, and 39 SOC hospitalized patients with hematological illnesses in India, showing no significant differences. Results were better for 24mg vs. 12mg for all symptomatic outcomes.
Viral clearance results do not follow the randomization with less than 50% of patients tested at day 7, and no adjusted results are provided. Results were obtained for only 43.8% of ivermectin patients and 56.4% of control patients at day 7 and may not be comparable due to the large difference in the percentage of patients tested. Lower test coverage in the ivermectin group is likely related to faster recovery. Ct 40 for E or S was used for viral clearance which may also have low relevance to infectious disease.
risk of death, 30.4% lower, RR 0.70, p = 0.55, treatment 5 of 35 (14.3%), control 8 of 39 (20.5%), NNT 16, 24mg.
risk of death, 2.6% higher, RR 1.03, p = 1.00, treatment 8 of 38 (21.1%), control 8 of 39 (20.5%), 12mg.
recovery time, 18.7% lower, relative time 0.81, p = 0.37, treatment mean 4.82 (±4.35) n=35, control mean 5.93 (±5.93) n=39, 24mg.
recovery time, 6.2% lower, relative time 0.94, p = 0.78, treatment mean 5.56 (±5.42) n=38, control mean 5.93 (±5.93) n=39, 12mg.
risk of progression, 33.1% lower, RR 0.67, p = 0.41, treatment 6 of 35 (17.1%), control 10 of 39 (25.6%), NNT 12, 24mg.
risk of progression, 17.9% lower, RR 0.82, p = 0.79, treatment 8 of 38 (21.1%), control 10 of 39 (25.6%), NNT 22, 12mg.
risk of no viral clearance, 33.3% higher, RR 1.33, p = 0.50, treatment 10 of 15 (66.7%), control 11 of 22 (50.0%), subset of patients with a large difference between groups, day 7, 24mg.
risk of no viral clearance, 17.6% higher, RR 1.18, p = 0.75, treatment 10 of 17 (58.8%), control 11 of 22 (50.0%), subset of patients with a large difference between groups, day 7, 12mg.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
George et al., 5/27/2022, Randomized Controlled Trial, India, South Asia, peer-reviewed, 15 authors, study period June 2020 - February 2021, dosage 24mg single dose, trial CTRI/2020/05/025068.
All Studies   Meta Analysis
This PaperIvermectinAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop